hrp0095p1-291 | Fetal, Neonatal Endocrinology and Metabolism | ESPE2022

Bronchopulmonary dysplasia is not related to neurofilament light chain for neuroaxonal damage in preterm infants

Romijn Michelle , Baas Emma , Lissenberg-Witte Birgit , Onland Wes , Königs Marsh , Oosterlaan Jaap , Heijst Hans , Rotteveel Joost , van Kaam Anton , Teunissen Charlotte , Finken Martijn

Rationale: Bronchopulmonary dysplasia (BPD) is a common complication after preterm birth that is associated with neurodevelopmental impairment. Neurofilament light chain (NfL) has been identified as a biomarker for neuroaxonal damage in preterm infants, but its relation with BPD has not yet been established. We hypothesized that BPD is associated with increased NfL levels at an early stage, indicative of early neuroaxonal damage....

hrp0095p1-354 | Pituitary, Neuroendocrinology and Puberty | ESPE2022

Single centre experience of using 6 monthly GnRH analogues in the paediatric population

Apperley Louise , Dharmaraj Poonam , Blair Joanne , Ramakrishnan Renuka , Das Urmi , Didi Mohammed , Laing Peter , Yung Zoe , Cassidy Kelly , Blundell Pauline , Jarvis Charlotte , Parkinson Jennifer , Senniappan Senthil

Background: Mounting evidence points to an association between increased glucocorticoid (GC) action and weight gain. However, the response to GCs is not only determined by GC serum concentrations, but also by individual differences in tissue-specific sensitivity, influenced by genetic and acquired (e.g. disease-related) factors. The extent to which differences in GC sensitivity may influence development of (abdominal) obesity, or vice versa, is poorly understo...

hrp0095p2-270 | Sex Differentiation, Gonads and Gynaecology, and Sex Endocrinology | ESPE2022

What lessons from past history of patients with CAH in a Sub Saharan country?

Sap Suzanne , Mbono Ritha , Kamo Hélène , Tony Jocelyn , Eposse Charlotte , Epee Jeannette , Mekone Isabelle , Bodieu Adèle , Olivier Koki Paul

Introduction: Congenital adrenal hyperplasia is the most common cause of primary adrenal insufficiency. It is a rare monogenic recessive disorder. In African setting in absence of neonatal screening, the diagnosis is still late, based on a clinical approach. During this clinical enquiry, information form past history or pedigree of the patient are of a huge importance and may revealed surprisesPatients and methods: In th...

hrp0082p1-d3-198 | Pituitary | ESPE2014

Spatial and Temporal Expression of Immunoglobulin Superfamily Member 1 in the Rat

Joustra Sjoerd , Meijer Onno , Oostdijk Wilma , Heinen Charlotte , Mol Isabel , Carreno Gabriela , Bernard Daniel , Biermasz Nienk , van Pelt Ans , Hamer Geert , Wit Jan Maarten , Wagenaar Gerry

Background: Loss-of-function of immunoglobulin superfamily member 1 (IGSF1) results in an X-linked syndrome of central hypothyroidism and macroorchidism, variable prolactin deficiency, GH deficiency, increased fat percentage, and delayed puberty testosterone rise despite normal timing of testicular growth.Methods: We investigated the spatial and temporal expression of IGSF1 at the protein and mRNA levels in fetal, neonatal, and adult Wistar rats, using i...

hrp0082p2-d1-420 | Growth Hormone | ESPE2014

S.c. Injections of a Reversible Albumin-Binding GH Derivative (NNC0195-0092) in Adult Subjects with GH Deficiency is Well Tolerated

Rasmussen Michael Hojby , Janukonyte Jurgita , Klose Marianne , Marina Djordje , Tanvig Mette , Nielsen Lene , Hoybye Charlotte , Andersen Marianne , Feldt-Rasmussen Ulla , Christiansen Jens

Background: Recombinant human GH (rhGH) is normally administered as a daily s.c. injection. NNC0195-0092 is a reversible albumin-binding GH derivative developed with the aim of reducing clearance and thereby extending the exposure. It has previously been demonstrated that NNC0195-0092 is well tolerated in healthy subjects with the potential for once weekly administration.Objective and hypotheses: In this trial NNC0195-0092 was administrated subcutaneousl...

hrp0095fc10.5 | GH and IGFs | ESPE2022

Features and outcomes of syndromic vs non-syndromic children born small for gestational age (SGA) under growth hormone therapy in a Belgian cohort

Becker Marianne , Thomas Muriel , Brachet Cécile , Heinrichs Claudine , Dotremont Hilde , Logghe Karl , Casteels Kristina , Rochtus Anne , Klink Daniel , Cools Martine , De Waele Kathleen , Parent Anne-Simone , Massa Guy , Staels Willem , Gies Inge , Lysy Philippe , Beckers Dominique

Background and Aim: A substantial proportion of SGA patients have a syndrome underlying their growth restriction. Most SGA cohorts comprise both syndromic (S-SGA) and non-syndromic patients (nonS-SGA) impeding delineation of the recombinant human growth hormone (rhGH) response. We present a detailed characterization of the Belgian SGA cohort and analyze rhGH response based on adult height (AH).Patients & Methods: Cli...

hrp0095p1-43 | Diabetes and Insulin | ESPE2022

The spectrum of paediatric diabetes subtypes from a single center in a highly consanguineous region

Anne Amaratunga Shenali , Hussein Tayeb Tara , Nabaz Muhamad Sediq Rozhan , Karem Hama Salih Fareda , Dusatkova Petra , Pruhova Stepanka , Lebl Jan

Introduction: Monogenic diabetes has been estimated to be 1 - 6% of all diabetic cases in European countries which are primarily non consanguineous populations, while the incidence in highly consanguineous areas is insufficiently defined. However, the genetic aetiology of monogenic diabetes has been shown to be widely different in areas with prevalent consanguinity compared to areas with lower rates. In this single-centre study, we aimed to evaluate the preval...

hrp0095p1-118 | Growth and Syndromes | ESPE2022

A background review of several generic patient-reported outcome and clinician-reported outcome measures: Selecting measures for further evaluation in a qualitative study in achondroplasia.

D. Mathias Susan , Hoover-Fong Julie , Savarirayan Ravi , Cho Terry , Lee Anne , H. Colwell Hilary , Rogoff Daniela , Muslimova Elena

Objectives: No validated achondroplasia (ACH)-specific patient reported outcome (PRO) or clinician-reported outcome (ClinRO) measures are available. A detailed review of generic PRO and ClinRO measures was performed to select relevant tools for further evaluation in a qualitative study.Methods: Published literature describing medical challenges and impacts among children with ACH was reviewed to identify important concep...

hrp0092rfc2.2 | Bone, Growth Plate and Mineral Metabolism Session 1 | ESPE2019

Does the Treatment with Recombinant Human Growth Hormone Improve Final Height in Patients Affected by X-Linked Hypophosphatemia?

André Julia , Zhukouskaya Volha V. , Rothenbuhler Anya , Lambert Anne-Sophie , Salles Jean-Pierre , Mignot Brigitte , Linglart Agnès

Background/Aim: 25 to 40% of children with well-controlled X-linked hypophosphatemia (XLH) show linear growth failure, despite optimal conventional treatment (oral phosphate supplementation and active forms of vitamin D) with final height -2 SDS. Recombinant human growth hormone (rhGH) may be an adjuvant treatment of the growth retardation in these patients. Therefore, the main objective of this study was to describe how rhGH treatment improves final heigh...

hrp0086rfc2.8 | Bone & Mineral Metabolism | ESPE2016

Final Heights and BMI in Patients Affected with Different Types of Pseudohypoparathyroidism

Hanna Patrick , Mantovani Giovanna , Grybek Virginie , Juppner Harald , Brehin Anne-Claire , Kottler Marie-Laure , Rothenbuhler Anya , Linglart Agnes

Background: Pseudohypoparathyroidism type 1A (PHP1A) and PseudoPHP are caused respectively by maternal and paternal mutations involving those GNAS exons that encode the alpha-subunit of the stimulatory G protein (Gsα). Common to different forms of PHP1B is a loss-of-methylation (LOM) at one or several maternal GNAS exons, which likely reduces Gsα expression in certain tissues. In most autosomal dominant PHP1B variants (AD-PHP1B), LOM is restricted t...